Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection.
Third Round of Late-Breaking Clinical Trial Results Announced at VIVA23 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
First-on-Podium Data from 20 Vascular and Venous Clinical Trials to Be Presented at The VEINS and VIVA 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Leading physicians and researchers will present results from 20 clinical trials from Monday, October 30, to Wednesday, November 1, at the.